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Abstract
Background: Huntington disease (HD) is a fully penetrant, autosomal dominantly inherited
disorder associated with abnormal expansions of a stretch of perfect CAG repeats in the 5' part of
the IT15 gene. The number of repeat units is highly predictive for the age at onset (AO) of the
disorder. But AO is only modestly correlated with repeat length when intermediate HD
expansions are considered. Recently, suggestive association has been reported between a single
nucleotide polymorphism (SNP; rs1801131, also known as A1298C) in the methyltetrahydrofolate
reductase (MTHFR) gene and AO of HD. 5,10-MTHFR is a key enzyme in the folate metabolism,
diverting metabolites toward methylation reactions or nucleotide synthesis. Using part of a
previously established study cohort plus additional patients and appropriate statistical methods, we
reinvestigated two polymorphisms in the MTHFR gene, C677T and A1298C, as well as their
association with AO in 167 HD patients.
Results: There was no statistically significant impact on AO for HD patients, neither of MTHFR
SNPs nor of the combinations thereof.
Conclusion: Contrary to previously described evidence the A1298C polymorphism in the MTHFR
gene does not appear to modulate AO of HD patients.
Background
Huntington disease (HD) is caused by expansion of a
cytosine-adenine-guanine (CAG) trinucleotide repeat in
the 5'-translated region of the IT15 gene on chromosome
4, which encode the protein huntingtin [1]. The expan-
sions result in the formation of elongated proteins with a
variety of new properties. The extent of the expansion is
inversely correlated with the age of onset (AO). Neverthe-
less, large part of the variance in AO remains unexplained
[2]. The pathogenesis of HD has been implicated to relate
to different aspects of the homocysteine metabolism: Cys-
tathionine [beta]-synthase (CBS) appears to bind specifi-
cally to huntingtin (htt) [3]. CBS deficiency is associated
with homocystinuria, which affects various physiological
systems, including the central nervous system. Homo-
cysteine, one of the substrates of CBS accumulates in
homocystinuria and is metabolized to homocysteate and
homocysteine sulphinate, both components of which are
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context homocysteine was suggested to influence the
pathogenesis of HD. Two common polymorphisms have
been described in the MTHFR gene, both single nucle-
otide substitutions resulting in amino acid changes
(C677T → Ala222Val and A1298C → Glu429Ala) [4,5].
Whereas C677T unequivocally affects enzyme function
and has been associated with increased plasma homo-
cysteine concentrations and an altered balance of folate
metabolites [4], the functional relevance in vivo of the
A1298C allele is less well defined. A1298C affects enzyme
function in vitro to a lesser degree, and individuals carry-
ing the variation have frequently normal homocysteine
and plasma folate concentrations [6,7]. It is unclear
whether the substitution affects folate metabolism under
specific physiological conditions, e.g. under low nutrient
intake. Apparently, the 677C→T and the 1298A→C poly-
morphisms can act synergistically, given that heterozygos-
ity for both polymorphisms causes lower MTHFR
enzymatic activity than heterozygosity alone for either of
them and a trend to higher or significantly higher plasma
total homocysteine levels [8].
Brune et al. reported recently an association between the
homozygous A1298C allele and a distinctly lower AO
compared to the wild type MTHFR genotypes [9]. In the
present study we re-examined the 1298A→C polymor-
phism as well as its potential interaction with the
677C→T polymorphism as genetic factors influencing the
AO of HD. Compared to the patient cohort examined by
Brune et al. (n = 171), here 27 patients have been
excluded from the initial cohort due to relatedness (the
first diagnosed family member remained in this study)
and lacking information on the motor age at onset. In
contrast to the initial cohort, exclusively the motor AO
was referred to. The present cohort (n = 167) has been
supplemented by 23 patients due to recruitment of new
patients. The potential influence of certain genotypes on
AO was calculated by linear regression, in which R2 illus-
trates the relative improvement of the regression model
when the various genotypes are considered in addition to
the HD CAG repeats.
Results and discussion
Analysis of the MTHFR 677C→T and the 1298A→C poly-
morphisms in 167 patients revealed allele frequencies of
0.35 for MTHFR 677T and 0.29 for MTHFR 1298C,
respectively. Observed frequencies were in Hardy-Wein-
berg equilibrium.
The prevalences of the combined MTHFR genotypes for
patients and controls are listed in Table 1. 23.3% of the
subjects represented combined heterozygotes for the two
SNPs (1298AC/677CT). We found no double
homozygous individuals (1298CC/677TT) and no
patient carrying the 1298CC/677CT genotype, a result to
be expected based on genotype frequencies reported in
other populations [11,12]. Thus our findings comply with
the suspicion that these two polymorphisms occur rarely
in cis [7]. Addition of the MTHFR genotype variations,
alone and in combination (data only shown for the dom-
inant model of the rare allele or the model for compound
heterozygosity, respectively) to the effect of CAG repeat
lengths resulted in no significant increase in the R2 value
(Table 2). Hence, this study failed to replicate the associa-
tion finding between the genotypes of the A1298C poly-
morphism in MTHFR with the AO of HD. Since our
cohort comprises mostly the same individuals as investi-
gated before (144/167), the initial description of associa-
tion is due to weaker exclusion criteria concerning
relatedness of patients as well as exclusive reference to
motor AO. In addition different statistical principles were
employed.
Table 2: Linear regression analysis concerning polymorphisms in the MTHFR gene
Gene (polymorphism) R2 ∆R2 % additional explained variance P value
HD CAG .308 - < .0005
HD CAG + MTHFR A1298C .304 .004 - .850
HD CAG + MTHFR C677T .305 .003 - .590
HD CAG + compound heterozygotes .304 .004 - .828
Variance in age at onset for the CAG repeats is indicated as such as well as in combination with the different polymorphisms examined. R2 
illustrates the relative improvement of the regression model when the various genotypes are considered in addition to the HD CAG repeats, ∆R2 
values quantify these differences. P values refer to R2.
Table 1: Number of different genotype combinations of the 
MTHFR 677C→Ta and 1298 A→Cb polymorphism in 167 HD 
patients
MTHFR 677CC (%) 677CT (%) 677TT (%)
genotype n = 71 n = 75 n = 21
1298AA (n = 80) 23 (13.7) 37 (22.1) 20 (12)
1298AC (n = 74) 35 (21) 38 (22.8) 1 (0.6)
1298CC(n = 13) 13(7.8) 0 0
aAllele frequency of MTHFR 677T amounts to 0.35.
bAllele frequency of MTHFR 1298C amounts to 0.29.Page 2 of 3
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We failed to replicate the association finding between the
1298CC genotype in the MTHFR gene and earlier AO in
HD. In future studies in this context, also the folate levels
of individual patients should be taken into account as
well as environmental factors.
Methods
One hundred sixty-seven patients clinically diagnosed as
suffering from HD were ascertained for their motor AO in
the Huntington Center (HZ) NRW, Bochum (Germany)
[10]. All patients gave informed consent for genotyping.
The CAG repeat sizes and the MTHFR A1298C and C677T
genotypes were determined as described before [9]. The
dependence of the AO on CAG repeat number was deter-
mined by linear regression. Residuals from this model
were verified, and there was no evidence of departure
from normality and equality of variance assumptions. The
possible genotypic effects of the two polymorphisms were
assessed with multiple linear regressions, while allowing
for the predictive effects of the CAG repeat size. We used
the AO as dependent variable and the respective geno-
types as independent variables. The CAG repeat number
was considered as numerical variable. All of the other
putatively modifying genotypes were considered as nom-
inal variables by assigning the value "0, 1" or "0, 1, 2"
according to the subject's number of variant alleles under
a model of dominance or otherwise according to a model
of generalized additive allelic effect. SPSS Ver.11.0 for
Windows (SPSS Inc.) was used for all statistical analyses.
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